TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04722575

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cobimetinib 20 MG Oral Tablet
Description: Cobimetinib 60 mg qd p.o. from week 1 to week 3 and week 5 to week 6. Week 4 off.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cobimetinib 20 MG Oral Tablet
Description: Cobimetinib 60 mg qd p.o. from week 1 to week 3 and week 5 to week 6. Week 4 off.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cobimetinib 20 MG Oral Tablet
Description: Cobimetinib 60 mg qd p.o. from week 1 to week 3 and week 5 to week 6. Week 4 off.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vemurafenib 240 Mg Oral Capsule
Description: 960 (arm A) /720 (arm B) mg bid p.o. from week 1 to week 6.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vemurafenib 240 Mg Oral Capsule
Description: 960 (arm A) /720 (arm B) mg bid p.o. from week 1 to week 6.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab 1200 MG in 20 ML Injection
Description: 840 mg IV for 2 cycles for Arm B and C. After surgery in all arms 1200 mg IV for 52 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab 1200 MG in 20 ML Injection
Description: 840 mg IV for 2 cycles for Arm B and C. After surgery in all arms 1200 mg IV for 52 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab 1200 MG in 20 ML Injection
Description: 840 mg IV for 2 cycles for Arm B and C. After surgery in all arms 1200 mg IV for 52 weeks
Study: NCT04227262

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: MIRROR THERAPY
Description: The children were instructed to sitting on chair and a mirror is placed in midsagittal plane of the child, with the normal limb in front of mirror and the affected limb is blocked so the patient see only the reflected movement of the sound limb (non affected).
Study: NCT01353820

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: 1- Low fat drinkable fermented by Lactobacillus Delbruckii lactis (DN111244) - >10E8 <5.10E9 cfu/mL
Description: 1- Intervention with test product ( \>10E8 to \<5.10E9 cfu/ml of L. delbruckii lactis )

Intervention type: DIETARY_SUPPLEMENT
Group type: SHAM_COMPARATOR
Intervention: 2- Low fat drinkable fermented by S. thermophilus and L. bulgaricus
Description: 2- Intervention with control product
Study: NCT01053390

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Somatostatin
Description: Somatostatin 3mg+NS（normal saline）60ml, a continuous intravenous infusion, q12h

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: epirubicin, cisplatin, LV（Leucovorin）、 5-FU（5-Fluorouracil）

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: epirubicin, cisplatin, LV（Leucovorin）、 5-FU（5-Fluorouracil）
Study: NCT04474756

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: custom-made adjustable mandibular advancement device
Description: a custom-made mandibular repositioning device (MRD), available under medical prescription for the treatment of adult obstructive sleep apnea (OSA) and snoring. It maintains the mandible in an advanced position along the occlusal plane. This ensures patient comfort and treatment efficacy.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: custom-made adjustable mandibular advancement device
Description: a custom-made mandibular repositioning device (MRD), available under medical prescription for the treatment of adult obstructive sleep apnea (OSA) and snoring. It maintains the mandible in an advanced position along the occlusal plane. This ensures patient comfort and treatment efficacy.
Study: NCT03879733

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Thrive by Three
Description: The intervention consists of the following components:~1. Measurement of daycare quality with CLASS (Classroom Assessment Scoring System) 3 times during the intervention period~2. Feedback to group staff on 8 CLASS-quality dimensions~3. Monthly supervision of staff on two levels: supervision of daycare staff, and supervision of supervisors~4. Competence building with all staff: 3 full training days, plus 2 extra training days for pedagogical leaders/supervisors~5. Written material to parents, supervisors, and staff~6. Web page for staff and parents: tf3.no

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Treatment as usual (TAU)
Description: The wait-list control group will continue with their daily activities and work in the childcare as usual. The wait list control group will have received general information about the study prior to consenting, however no materials or are provided by project. The child-care centers in the control conditions will receive a gift certificate of 3000 Norwegian Crones (NOK) by the end of the intervention period.
Study: NCT04247061

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Educational video
Description: One of two different 10 minute educational videos on smoking cessation will be viewed by participants during a dental cleaning visit. The video that is watched will depend on participants' level of motivation to quit and project needs

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Text-message program
Description: A one-month text message program to motivate and facilitate contact with smoking cessation resources.
Study: NCT04496401

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tacrolimus and Tacrolimus Extended Release Oral Tablet [Envarsus]
Description: Phase 1: standard dose and frequency tacrolimus, used in accordance with licensing and local protocols. Suitable target trough level should be between 7-14 ng/ml.~Phase 2: ENVARSUS® (LCP Tacro - extended release tacrolimus), used once-daily at an initial dose of 0.17mg/kg, dose adjusted to maintain an appropriate therapeutic blood concentration (measured by trough level). Suitable target trough level should be between 7-14 ng/ml.
Study: NCT01189188

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Artery puncture with ultrasound guidance
Description: Ultrasound device will be used to locate artery for puncture.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Artery puncture without ultrasound guidance
Description: Blood drawn from radial artery according to conventional procedure, without ultrasound guidance.
Study: NCT01303042

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Insulin lispro mix 50/50
Description: Insulin lispro mix 50/50 t.i.d : six months
Study: NCT02512224

Intervention type: DEVICE
Intervention: Parenteral nutrition
Description: Participants are retrospectively selected with propensity score matching

Intervention type: DEVICE
Intervention: Enteral nutrition
Description: Participants are retrospectively selected with propensity score matching
Study: NCT04173676

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Indocyanine Green for Injection
Description: The sentinel lymph nodes were observed by submucosal injection of ICG
Study: NCT00263029

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: 60mg/m² as a 2-hour intravenous infusion every week for 5-6 week

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: 500mg tablets and 150mg tablets. 750mg/m² bd given approximately 12 hours apart

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiotherapy
Description: Planned total dose of 45-50.4Gy (with cone down) in 25-28 fractions
Study: NCT00730964

Intervention type: DRUG
Group type: OTHER
Intervention: Perflutren Protein-Type A Microspheres Injectable Suspension, United States Pharmacopeia (USP)
Description: The recommended dose of Optison is 0.5mL injected into a peripheral vein. This may be repeated for further contrast enhancement as needed.~The injection rate should not exceed 1mL per second. Follow the Optison injection with a flush of 0.9% sodium chloride injection, USP or 5% dextrose in water injection, United States Pharmacopeia (USP) .~The maximum total dose should not exceed 5.0mL in any 10 minutes period. The maximum total dose should not exceed 8.7mL in any one patient study.
Study: NCT01925690

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Motivational Interviewing-Cognitive Behavioral Therapy
Description: A telephone based talk therapy discussing pros and cons of medication use in MS.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Brief Education
Description: Give patients a pamphlet discussing pros and cons of disease modifying therapies

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Brief Education
Description: Give patients a pamphlet discussing pros and cons of disease modifying therapies
Study: NCT02079857

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard protocol
Description: Subjects will receive a standard treatment

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Individualized protocol
Description: Subjects will receive an individualized treatment

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham acupuncture/Placebo moxa
Description: Subjects will receive sham acupuncture/placebo moxa
Study: NCT03397004

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Doxycycline Hyclate
Description: Doxycycline will be given for 6 months, followed by a washout period for 6 months (pre or post a crossover intervention)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo will be given for 6 months, followed by a washout period for 6 months (pre or post a crossover intervention)
Study: NCT02943564

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rapastinel
Description: Rapastinel pre-filled syringes for weekly IV injections.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rapastinel
Description: Rapastinel pre-filled syringes for weekly IV injections.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo-matching rapastinel pre-filled syringes for weekly IV injections.
Study: NCT03385603

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Dilator
Description: Both groups will have a home program consisting of dilators which are progressive in size. The standard care group will use manufacturer instructions to progress in size of dilators, while the experimental group will use self-reported levels of fear to progress in size of dilators.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Dilator
Description: Both groups will have a home program consisting of dilators which are progressive in size. The standard care group will use manufacturer instructions to progress in size of dilators, while the experimental group will use self-reported levels of fear to progress in size of dilators.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Fear-Based Questionnaires
Description: Series of questionnaires used to facilitate emotional awareness associated with vaginal and decreased sexual arousal.
Study: NCT02461550

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Irreversible Electroporation Ablation
Study: NCT04066036

Intervention type: OTHER
Intervention: This is an observational study only.
Description: This is an observational study only.
Study: NCT01567657

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: pethidin hydrochlorid, midazolam
Description: Pethidin hydrochlorid: 25 mg iv. at the beginning of the examination Midazolam: 1-2 mg iv. at the beginning of the examination. Repetitive given in a dosis of 1 mg iv. until a total amount of 7 mg iv.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Propofol
Description: 50 years and over: initial dose of 50-60 mg Propofol iv. Followed by bolus of 20-30 mg iv. until sedation is achieved.~\< 50 years: initial dose 30-40 mg Propofol iv. Followed by bolus of 10-20 mg until sedation is achieved.
Study: NCT04721470

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Combined therapy
Description: Patients undergoing combined therapy

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Microwave ablation
Description: Patients undergoing Microwave ablation

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Transarterial chemoembolization
Description: Patients undergoing Transarterial chemoembolization
Study: NCT04662658

Intervention type: DRUG
Group type: OTHER
Intervention: Hyperpolarized Xenon -129 MRI
Description: e-cigarette sub-study

Intervention type: DRUG
Group type: OTHER
Intervention: Hyperpolarized Xenon -129 MRI
Description: e-cigarette sub-study
Study: NCT01252745

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 10.0 mg of Testosterone, 4.0% TID

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 13.5 mg of Testosterone, 4.5% B.I.D

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 11.25 mg of Testosterone, 4.5% T.I.D
Study: NCT03163589

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Erythropoietin
Description: injection

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: normal saline
Description: injection
Study: NCT03491007

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: DHEA
Description: Subjects will be randomized to receive a one-time oral dose of DHEA (400mg) or PBO and sustained administration of the study drug for 6 weeks. There will be a 2 week placebo lead-in period \[all participants\], followed by subjects continuing in the randomization block of DHEA or placebo for 6 weeks following acute administration).
Study: NCT02625233

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: senofilcon C

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: comfilcon A
Study: NCT01833442

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Kundalini Yoga Meditation
Description: The trial will compare two very different meditation protocols. After the 4.5 month the patients will be reevaluated, and all patients will be merged together into a single group. Patients will then receive 9 - 12 more months of the meditation protocol.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Relaxation Response Meditation
Description: The trial will compare two very different meditation protocols. After the 4.5 month the patients will be reevaluated, and all patients will be merged together into a single group. Patients will then receive 9 - 12 more months of the meditation protocol.
Study: NCT02802748

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oral Vinorelbine
Description: Metronomic Schedule of Vinorelbine administered orally in a schedule monday-wednesday-friday, tuesday-thursday-saturday, etc

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oral Vinorelbine
Description: Metronomic Schedule of Vinorelbine administered orally in a schedule monday-wednesday-friday, tuesday-thursday-saturday, etc

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Letrozole
Description: Letrozole will be administered orally at 2.5 mg QD for 3 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Letrozole
Description: Letrozole will be administered orally at 2.5 mg QD for 3 weeks.
Study: NCT01552291

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Glutamine
Description: 30g oral glutamine / day for 5 days before surgery. Glutamine is an important nonessential amino acid and its intracellular concentration is much higher than that of other amino acids. Glutamine is released in large quantities from skeletal muscle and serves as an important carrier and donor of nitrogen

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 30g oral maltodextrin / day for 5 days before surgery
Study: NCT01794611

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: laryngoscopy
Study: NCT01379469

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Drug-Carbamazepine (Tegretol XR)
Description: To reduce the likelihood of hypersensitivity reactions the subjects will be started on 400 mg/day in 2 doses and the dose will be increased weekly by 200mg/day until reaching a stable therapeutic concentration with a dose not exceeding 1200mg/day(or 1000mg/day in subjects less than 15 years of age). The CBZ tablets will be encapsulated..

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Carbamazepine (Tegretol XR) Placebo
Description: Carbamazepine (Tegretol XR)Placebo-the subjects will be started on 400mg/day in 2 doses and the dose will be increased weekly by 200 mg/day until reaching a dose not exceeding 1200 mg/day (or 1000 mg/day in subjects less than 15 years of age). The placebo group will receive encapsulated tables without Carbamazepine.
Study: NCT01666431

Intervention type: DRUG
Group type: OTHER
Intervention: Lapatinib
Study: NCT00432042

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: ProQuad®
Description: Participants received a 0.5 mL subcutaneous injection of ProQuad® containing the following live attenuated virus strains: measles virus Enders' Edmonston strain (≥3.00 log10 50% cell culture infectious dose \[CCID\]50), mumps virus Jeryl Lynn™ (Level B) strain (≥4.30 log10 CCID50), rubella virus Wistar RA 27/3 strain (≥3.00 log10 CCID50), and varicella virus Oka/Merck strain (≥3.99 log10 plaque-forming units \[PFU\]).

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ProQuad®
Description: Participants received a 0.5 mL subcutaneous injection of ProQuad® containing the following live attenuated virus strains: measles virus Enders' Edmonston strain (≥3.00 log10 50% cell culture infectious dose \[CCID\]50), mumps virus Jeryl Lynn™ (Level B) strain (≥4.30 log10 CCID50), rubella virus Wistar RA 27/3 strain (≥3.00 log10 CCID50), and varicella virus Oka/Merck strain (≥3.99 log10 plaque-forming units \[PFU\]).

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Infanrix® hexa
Description: Participants received a 0.5 mL intramuscular injection of Infanrix® hexa containing the following: diphtheria toxoid (≥30 IU), tetanus toxoid (≥40 IU), 3-component acellular pertussis (pertussis taxoid, filamentous haemagglutinin, and pertactin) (25 ug), Hepatitis B surface antigen recombinant (S protein) (10 ug), inactivated poliovirus types 1-3 (type 1: 40 D-antigen units; type 2: 8 D-antigen units; type 3: 32 D-antigen units), and Haemophilus influenzae type B (Hib) polysaccharide conjugate to tetanus toxoid (20-40 ug).

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Infanrix® hexa
Description: Participants received a 0.5 mL intramuscular injection of Infanrix® hexa containing the following: diphtheria toxoid (≥30 IU), tetanus toxoid (≥40 IU), 3-component acellular pertussis (pertussis taxoid, filamentous haemagglutinin, and pertactin) (25 ug), Hepatitis B surface antigen recombinant (S protein) (10 ug), inactivated poliovirus types 1-3 (type 1: 40 D-antigen units; type 2: 8 D-antigen units; type 3: 32 D-antigen units), and Haemophilus influenzae type B (Hib) polysaccharide conjugate to tetanus toxoid (20-40 ug).
Study: NCT02287389

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: balloon dilation

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: balloon dilation

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: balloon dilation

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: balloon dilation

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: cryotherapy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: spiculiform electrosurgery

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mitomycin C
Study: NCT00763750

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PPX +TMZ+XRT
Description: PPX 50 mg/m2/week x 6 weeks (Days #1, 8, 15, 22, 29, 36) XRT: 60 Gy at 2 Gy/fraction x 30 fractions Temozolomide 75 mg/m2/day: Day #1 of XRT until completion (including weekends and holidays)
Study: NCT02648802

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Cavity shaving
Description: Resect the residual cavity circumferentially (superior, inferior, medial, lateral) and the thickness of the cavity shaving depends on the surgeon's discretion (Recommended 0.5-1.0cm). The principles of the cavity shaving includes: 1) do not compromise the cosmetic outcomes; 2) covers the entire cavity;
Study: NCT04299607

Intervention type: DIAGNOSTIC_TEST
Intervention: DPP Fever Panel II assay and DPP Micro Readers
Description: Detection of common causes of acute febrile illnesses in Asia
Study: NCT01238926

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: PD vitamin supplementation
Description: 25 mg/day of Vitamin B6 2,000 mcg/day of Vitamin B12 5 mg/day of Folic Acid

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: PD exercise intervention
Description: Cardiovascular training (treadmill and StairMaster), 20 min; and strength training (2 sets of 15 repetitions of 60-70% of 1 repetition maximum \[RM\]) using machines that provide the following motions: knee extension, knee flexion, leg press, elbow flexion, elbow extension, seated dip.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: PD vitamin + exercise
Description: 25 mg/day of Vitamin B6 2,000 mcg/day of Vitamin B12 5 mg/day of Folic Acid Cardiovascular training (treadmill and StairMaster), 20 min; and strength training (2 sets of 15 repetitions of 60-70% of 1 repetition maximum \[RM\]) using machines that provide the following motions: knee extension, knee flexion, leg press, elbow flexion, elbow extension, seated dip.
Study: NCT02648802

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Standardized BCS+CM assessment.
Description: For standardized BCS(Chen K, et al. Ann Surg Oncol. 2012), we resect a rim of 1 cm macroscopically normal tissue around the tumor. The anterior and posterior margins of the tumor-containing specimen extended up to the subdermal plane of the skin and down to the pectoralis major fascia, respectively. The anterior and posterior CMs assessment will not be needed. A surgical blade was used for resecting the CMs (superior, inferior, medial and lateral) to render the thickness of the CMs as thin as possible. No procedures were required for distinguishing the inner and outer surface. They were then frozen and cut parallel, but not perpendicular to the largest surface area. CMs were defined as positive when in situ or invasive carcinoma was found intraoperatively by frozen-section analysis.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Standardized BCS+CM assessment.
Description: For standardized BCS(Chen K, et al. Ann Surg Oncol. 2012), we resect a rim of 1 cm macroscopically normal tissue around the tumor. The anterior and posterior margins of the tumor-containing specimen extended up to the subdermal plane of the skin and down to the pectoralis major fascia, respectively. The anterior and posterior CMs assessment will not be needed. A surgical blade was used for resecting the CMs (superior, inferior, medial and lateral) to render the thickness of the CMs as thin as possible. No procedures were required for distinguishing the inner and outer surface. They were then frozen and cut parallel, but not perpendicular to the largest surface area. CMs were defined as positive when in situ or invasive carcinoma was found intraoperatively by frozen-section analysis.